HomeCompareMBXBF vs ARCC

MBXBF vs ARCC: Dividend Comparison 2026

MBXBF yields 1162.79% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MBXBF wins by $71037548.32M in total portfolio value
10 years
MBXBF
MBXBF
● Live price
1162.79%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71037548.35M
Annual income
$60,758,695,090,499.19
Full MBXBF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — MBXBF vs ARCC

📍 MBXBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMBXBFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MBXBF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MBXBF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MBXBF
Annual income on $10K today (after 15% tax)
$98,837.21/yr
After 10yr DRIP, annual income (after tax)
$51,644,890,826,924.31/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, MBXBF beats the other by $51,644,890,826,923.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MBXBF + ARCC for your $10,000?

MBXBF: 50%ARCC: 50%
100% ARCC50/50100% MBXBF
Portfolio after 10yr
$35518774.19M
Annual income
$30,379,347,545,250.18/yr
Blended yield
85.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

MBXBF
No analyst data
Altman Z
1.4
Piotroski
2/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MBXBF buys
0
ARCC buys
0
No recent congressional trades found for MBXBF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMBXBFARCC
Forward yield1162.79%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$71037548.35M$24.5K
Annual income after 10y$60,758,695,090,499.19$1.16
Total dividends collected$70267668.95M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MBXBF vs ARCC ($10,000, DRIP)

YearMBXBF PortfolioMBXBF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$126,979$116,279.07$11,381$541.15+$115.6KMBXBF
2$1,515,775$1,379,907.30$12,621$284.08+$1.50MMBXBF
3$17,016,490$15,394,610.53$13,827$145.31+$17.00MMBXBF
4$179,725,369$161,517,725.51$15,062$73.43+$179.71MMBXBF
5$1,786,627,353$1,594,321,207.48$16,364$36.89+$1786.61MMBXBF
6$16,723,791,389$14,812,100,121.30$17,757$18.49+$16723.77MMBXBF
7$147,473,158,468$129,578,701,682.00$19,258$9.25+$147473.14MMBXBF
8$1,225,690,132,710$1,067,893,853,149.49$20,880$4.63+$1225690.11MMBXBF
9$9,606,404,914,243$8,294,916,472,243.00$22,636$2.32+$9606404.89MMBXBF
10$71,037,548,348,739$60,758,695,090,499.19$24,539$1.16+$71037548.32MMBXBF

MBXBF vs ARCC: Complete Analysis 2026

MBXBFStock

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Full MBXBF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this MBXBF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MBXBF vs SCHDMBXBF vs JEPIMBXBF vs OMBXBF vs KOMBXBF vs MAINMBXBF vs HTGCMBXBF vs GBDCMBXBF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.